Scaffold hopping of α-rubromycin enables direct access to FDA-approved cromoglicic acid as a SARS-CoV-2 MPro inhibitor

Hani A. Alhadrami, Ahmed M. Sayed, Heba Al-Khatabi, Nabil A. Alhakamy, Mostafa E. Rateb*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
13 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Scaffold hopping of α-rubromycin enables direct access to FDA-approved cromoglicic acid as a SARS-CoV-2 MPro inhibitor'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science